Â÷¼¼´ë ½ÃÄý¼(NGS) ½ÃÀåÀº 2025-2030³âÀÇ ¿¹Ãø ±â°£ Áß CAGR 7.35%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
Â÷¼¼´ë ½ÃÄö¼´Â È®À强, Ãʰí󸮷®, °í¼ÓÀ» °¡´ÉÇÏ°Ô ÇÏ´Â Ãʺ´·Ä ½ÃÄö½Ì ±â¼úÀÔ´Ï´Ù. DNA »çÀü ½ÃÄö½ÌÀº Àüü ½ÃÄö½Ì ±â¹ý¿¡¼ °¡Àå Áß¿äÇÑ ´Ü°è Áß ÇϳªÀ̸ç, ´ÙÀ½ ½ÃÄö½Ì ¹ÝÀÀÀ» À§ÇÑ Àç·á¸¦ ÁغñÇÏ´Â °ÍÀ» Æ÷ÇÔÇÏ¿© Àüü À¯ÀüüÀÇ ´ºÅ¬·¹¿ÀƼµå ¼¿À» È®Á¤ÇÏ´Â µ¥ »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. Àü ¼¼°è¿¡¼ NGS´Â ÀÓ»ó ½ÇÇè½Ç ºÐ¼®, °Ë»ç ¹× Áúº´ Áø´Ü¿¡ Á¡Â÷ÀûÀ¸·Î ÅëÇյǰí ÀÖ½À´Ï´Ù. À¯Àüü ¾à¸®ÇÐÀº ½Å¾à °³¹ß °úÁ¤À» °¡¼ÓÈÇϱâ À§ÇØ ±¤¹üÀ§ÇÑ ³ë·ÂÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. °Ô³ð ¸ÅÇÎ ÇÁ·Î±×·¥, Â÷¼¼´ë ½ÃÄö½Ì ¿ëµµ, ÇコÄɾî ÁöÃâ, ±â¼ú ¹ßÀüÀº ¿¹Ãø ±â°£ Áß Â÷¼¼´ë ½ÃÄö½Ì ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇÒ °ÍÀÔ´Ï´Ù.
½ÃÀå µ¿Çâ :
- Â÷¼¼´ë ½ÃÄö¼ ½ÃÀåÀÇ ¼ºÀå: Â÷¼¼´ë ½ÃÄö¼ ½ÃÀåÀº ¿°±â¼¿ °áÁ¤À» ÅëÇÑ Àüü À¯Àüü ½ÃÄö½Ì ´É·ÂÀ¸·Î ÀÎÇØ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ °úÁ¤¿¡¼ Áß¿äÇÑ ´Ü°è´Â ÈÄ¼Ó ½ÃÄö½Ì ¹ÝÀÀÀ» À§ÇÑ »ùÇÃÀ» ÁغñÇÏ´Â DNA »çÀü ½ÃÄö½ÌÀ¸·Î, ½ÃÄö½Ì ÇÁ·ÎÅäÄÝÀÇ ÇÙ½É ´Ü°èÀÔ´Ï´Ù. Àü ¼¼°è¿¡¼ NGS´Â ÀÇ·á °Ë»ç ºÐ¼®, Áúº´ Æò°¡ ¹× Áø´Ü¿¡ ÅëÇյǰí ÀÖ½À´Ï´Ù. ¾à¹°À¯ÀüüÇп¡¼´Â ½Å¾à°³¹ßÀ» °¡¼ÓÈÇϱâ À§ÇØ NGS°¡ ³Î¸® Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. Áø´Ü ¿ª·®À» °ÈÇϱâ À§ÇÑ ¾÷°è ±â¾÷ÀÇ ÁÖ¿ä Çõ½Å°ú °³¹ßÀº ÇâÈÄ ¼ö³â°£ ½ÃÀå °³¹ßÀÇ Å« ¿øµ¿·ÂÀÌ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 3¿ù SOPHiA GENETICS´Â NGS¸¦ ÅëÇÑ Á¾¾ç ºÐ¼®À» ÁøÇàÇϱâ À§ÇØ Qiagen°ú Á¦ÈÞ¸¦ ¸Î¾ú½À´Ï´Ù. ÀÌ Á¦ÈÞ´Â QIAseq ½Ã¾à ±â¼ú°ú SOPHiA DDM Ç÷§ÆûÀ» °áÇÕÇÑ °ÍÀ¸·Î, °í°´Àº SOPHiA DDM(TM)À» ÅëÇØ ó¸®µÈ QIAseq ÆÐ³Î¿¡ ¾×¼¼½ºÇÒ ¼ö ÀÖ½À´Ï´Ù. ó¸®µÈ QIAseq ÆÐ³Î¿¡ Á¢±ÙÇÒ ¼ö ÀÖ½À´Ï´Ù. À̹ø ÆÄÆ®³Ê½ÊÀº ü¼¼Æ÷ µ¹¿¬º¯ÀÌ °ËÃâÀ» À§ÇÑ QIAseq Targeted DNA Pro ÆÐ³ÎÀ» Ȱ¿ëÇÏ¿© ¾Ï ¿µ¿ª¿¡¼ PARP ¾ïÁ¦Á¦¿¡ ¹ÝÀÀÇÒ ¼ö ÀÖ´Â µ¹¿¬º¯À̰¡ ÀÖ´Â Á¾¾çÀ» ½Äº°ÇÏ´Â ¹ÙÀÌ¿À¸¶Ä¿ °Ë»çÀÎ »óµ¿ ÀçÁ¶ÇÕ º¹±¸(HRR)¿¡ ÃÊÁ¡À» ¸ÂÃè½À´Ï´Ù.
- Áö¿ªº° ½ÃÀå ÀλçÀÌÆ®: Â÷¼¼´ë ½ÃÄö¼ ¼¼°è ½ÃÀåÀº ºÏ¹Ì, ³²¹Ì, À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«, ¾Æ½Ã¾ÆÅÂÆò¾çÀ¸·Î ±¸ºÐµË´Ï´Ù. ºÏ¹Ì´Â Àü ¼¼°è¿¡¼ NGSÀÇ ÁÖ¿ä ½ÃÀåÀ¸·Î ºÎ»óÇϰí ÀÖÀ¸¸ç, ÇâÈÄ ¼ö³â°£ ÀÌ ¿ìÀ§¸¦ À¯ÁöÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ÀÏ»óÀûÀÎ ÀÓ»ó Áø´Ü¿¡¼ NGS ±â¼úÀÇ Ã¤Åà Ȯ´ë°¡ ÁÖ¿ä ÃËÁø¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. ÀÌ Áö¿ª ½ÃÀå È®´ë´Â ¸¸¼ºÁúȯ ¹× °¨¿°¼º ÁúȯÀÇ À¯º´·ü Áõ°¡, À¯ÀüüÇп¡ ´ëÇÑ ÅõÀÚ Áõ°¡, ÁÖ¿ä »ê¾÷ ±â¾÷ÀÇ °ý¸ñÇÒ ¸¸ÇÑ ¹ßÀü µîÀÇ ¿äÀο¡ ÀÇÇØ ´õ¿í Áö¿øµÇ°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î ij³ª´Ù ¾Ï Çùȸ´Â 2024³â 6,600¸íÀÇ Ä³³ª´ÙÀÎÀÌ ¹éÇ÷º´ Áø´ÜÀ» ¹ÞÀ» °ÍÀ¸·Î ÃßÁ¤Çϰí ÀÖ½À´Ï´Ù. ¹Ý¸é, ¹Ì±¹ º¸°Çº¹ÁöºÎ´Â °°Àº ÇØ¿¡ 62,770¸íÀÇ ½Å±Ô ȯÀÚ°¡ ¹ß»ýÇÒ °ÍÀ¸·Î ¿¹»óÇϰí ÀÖÀ¸¸ç, ÀÌ´Â Àüü ½Å±Ô ¾Ï Áø´ÜÀÇ 3.1%¿¡ ÇØ´çÇÕ´Ï´Ù. ÀÌ·¯ÇÑ Áúº´ ºÎ´ã Áõ°¡´Â Çõ½ÅÀûÀÎ °ËÃâ ¹× Áø´Ü ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ¿© ¿¹Ãø ±â°£ Áß ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.
ÀÌ ¸®Æ÷Æ®¿¡¼ ´Ù·ç°í ÀÖ´Â ÁÖ¿ä ±â¾÷¿¡´Â Quest Diagnostics Incorporated, ARUP Laboratories, Applied Biological Materials, Inc.(ABM), Novogene Co.Ltd., Azenta Life Sciences(GENEWIZ), NanoString µîÀÌ ÀÖ½À´Ï´Ù.
ÀÌ º¸°í¼ÀÇ ÁÖ¿ä ÀåÁ¡
- ÀλçÀÌÆ® ºÐ¼® : °í°´ ºÎ¹®, Á¤ºÎ Á¤Ã¥ ¹× »çȸ°æÁ¦Àû ¿äÀÎ, ¼ÒºñÀÚ ¼±È£µµ, »ê¾÷º°, ±âŸ ÇÏÀ§ ºÎ¹®¿¡ ÃÊÁ¡À» ¸ÂÃá ÁÖ¿ä Áö¿ª ¹× ½ÅÈï Áö¿ªÀ» Æ÷°ýÇÏ´Â »ó¼¼ÇÑ ½ÃÀå ºÐ¼®À» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.
- °æÀï ±¸µµ: ¼¼°è ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇϰí ÀÖ´Â Àü·«Àû Àü·«À» ÀÌÇØÇϰí, ÀûÀýÇÑ Àü·«À» ÅëÇÑ ½ÃÀå ħÅõ °¡´É¼ºÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.
- ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ : ¿ªµ¿ÀûÀÎ ¿äÀΰú ¸Å¿ì Áß¿äÇÑ ½ÃÀå µ¿Çâ, ±×¸®°í À̵éÀÌ ÇâÈÄ ½ÃÀå ¹ßÀüÀ» ¾î¶»°Ô Çü¼ºÇÒ °ÍÀÎÁö¿¡ ´ëÇØ ¾Ë¾Æº¾´Ï´Ù.
- ½ÇÇà °¡´ÉÇÑ Á¦¾È: ÀλçÀÌÆ®¸¦ Àü·«Àû ÀÇ»ç°áÁ¤¿¡ Ȱ¿ëÇϰí, ¿ªµ¿ÀûÀΠȯ°æ ¼Ó¿¡¼ »õ·Î¿î ºñÁî´Ï½º ½ºÆ®¸²°ú ¸ÅÃâÀ» ¹ß±¼ÇÕ´Ï´Ù.
- ´Ù¾çÇÑ »ç¿ëÀÚ¿¡ ´ëÀÀ: ½ºÅ¸Æ®¾÷, ¿¬±¸±â°ü, ÄÁ¼³ÅÏÆ®, Áß¼Ò±â¾÷, ´ë±â¾÷¿¡ À¯ÀÍÇÏ°í ºñ¿ë È¿À²ÀûÀÔ´Ï´Ù.
¾î¶² ¿ëµµ·Î »ç¿ëµÇ´Â°¡?
»ê¾÷ ¹× ½ÃÀå ÀλçÀÌÆ®, »ç¾÷ ±âȸ Æò°¡, Á¦Ç° ¼ö¿ä ¿¹Ãø, ½ÃÀå ÁøÃâ Àü·«, Áö¿ªÀû È®Àå, ¼³ºñ ÅõÀÚ °áÁ¤, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ© ¹× ¿µÇâ, ½ÅÁ¦Ç° °³¹ß, °æÀïÀÇ ¿µÇâ
Á¶»ç ¹üÀ§
- 2022-2024³âÀÇ °ú°Å µ¥ÀÌÅÍ¿Í 2025-2030³âÀÇ ¿¹Ãø µ¥ÀÌÅÍ
- ¼ºÀå ±âȸ, °úÁ¦, °ø±Þ¸Á Àü¸Á, ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©, µ¿Ç⠺м®
- °æÀï»ç ½ÃÀå »óȲ, Àü·«, ½ÃÀå Á¡À¯À² ºÐ¼®
- °¢ ±¹°¡¸¦ Æ÷ÇÔÇÑ ºÎ¹® ¹× Áö¿ªº° ¸ÅÃâ ¼ºÀå ¹× ¿¹Ãø Æò°¡
- ±â¾÷ °³¿ä(Àü·«, Á¦Ç°, À繫Á¤º¸, ÁÖ¿ä °³¹ß µî)
¸ñÂ÷
Á¦1Àå ¼·Ð
- ½ÃÀå °³¿ä
- ½ÃÀåÀÇ Á¤ÀÇ
- Á¶»ç ¹üÀ§
- ½ÃÀå ¼¼ºÐÈ
- ÅëÈ
- ÀüÁ¦Á¶°Ç
- ±âÁØ¿¬µµ¿Í ¿¹Ãø¿¬µµ ŸÀÓ¶óÀÎ
- ÀÌÇØ°ü°èÀÚ¿¡ ´ëÇÑ ÁÖ¿ä ÀÌÁ¡
Á¦2Àå Á¶»ç ¹æ¹ý
- Á¶»ç µðÀÚÀÎ
- Á¶»ç ÇÁ·Î¼¼½º
Á¦3Àå °³¿ä
- ÁÖ¿ä Á¶»ç °á°ú
- ¾Ö³Î¸®½ºÆ® ºä
Á¦4Àå ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
- Porter's Five Forces ºÐ¼®
- ¾÷°è ¹ë·ùüÀÎ ºÐ¼®
Á¦5Àå Â÷¼¼´ë ½ÃÄý¼ ½ÃÀå : Á¦°øº°
Á¦6Àå Â÷¼¼´ë ½ÃÄý¼ ½ÃÀå : ±â¼úº°
- ¼·Ð
- ÇÕ¼º¿¡ ÀÇÇÑ ½ÃÄö½Ì
- À̿ ¹ÝµµÃ¼ ½ÃÄö½Ì
- ´ÜÀÏ ºÐÀÚ ½Ç½Ã°£ ½ÃÄö½Ì
- ³ª³ëÆ÷¾î ½ÃÄö½Ì
- ±âŸ
Á¦7Àå Â÷¼¼´ë ½ÃÄý¼ ½ÃÀå : ¿ëµµº°
- ¼·Ð
- Áø´Ü
- Drug Discovery
- ¹ÙÀÌ¿À¸¶Ä¿ ¹ß°ß
- ³ó¾÷°ú µ¿¹° Á¶»ç
- ±âŸ
Á¦8Àå Â÷¼¼´ë ½ÃÄý¼ ½ÃÀå : ÃÖÁ¾»ç¿ëÀÚº°
- ¼·Ð
- º´¿ø¡¤Å¬¸®´Ð
- Á¦¾à¡¤¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
- Çмú±â°ü ¹× Á¶»ç±â°ü
- ±âŸ
Á¦9Àå Â÷¼¼´ë ½ÃÄý¼ ½ÃÀå : Áö¿ªº°
- ¼¼°è °³¿ä
- ºÏ¹Ì
- ³²¹Ì
- À¯·´
- ¿µ±¹
- µ¶ÀÏ
- ÇÁ¶û½º
- ½ºÆäÀÎ
- ±âŸ
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
- »ç¿ìµð¾Æ¶óºñ¾Æ
- ¾Æ¶ø¿¡¹Ì¸®Æ®
- À̽º¶ó¿¤
- ±âŸ
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ÀϺ»
- Áß±¹
- Àεµ
- Çѱ¹
- Àεµ³×½Ã¾Æ
- ű¹
- ±âŸ
Á¦10Àå °æÀï ȯ°æ°ú ºÐ¼®
- ÁÖ¿ä ±â¾÷°ú Àü·« ºÐ¼®
- ½ÃÀå Á¡À¯À² ºÐ¼®
- ÇÕº´, Àμö, ÇÕÀÇ ¹× Çù¾÷
- °æÀï ´ë½Ãº¸µå
Á¦11Àå ±â¾÷ °³¿ä
- Quest Diagnostics Incorporated
- ARUP Laboratories
- Applied Biological Materials, Inc.(ABM)
- Novogene Co., Ltd.
- Azenta Life Sciences(GENEWIZ)
- NanoString
- Illumina, Inc.
- PacBio
- Qiagen
- Thermo Fisher Scientific
KSA
The next-generation sequencers market is expected to grow at a CAGR of 7.35% during the projected period from 2025 to 2030.
Next-generation sequencing (NGS) is a massively parallel sequencing technology that enables scalability, ultra-high throughput, and quick speed. It can be used to establish the order of the nucleotides in the complete genome. DNA pre-sequencing is one of the most crucial steps in the entire sequencing methodology, which involves preparing the material for the following sequencing reaction. Globally, NGS is being gradually included in clinical laboratory analysis, testing, and illness diagnosis. Pharmacogenomics has made extensive efforts to speed up the drug discovery process. Genome mapping programs, next-generation sequencing applications, healthcare spending, and technology improvements are the main factors driving the next-generation sequencers market growth during the projected period.
Market Trends:
- Growth of the Next-Generation Sequencing Market: The next-generation sequencing (NGS) market is expanding due to its ability to sequence entire genomes by determining nucleotide sequences. A critical step in this process is DNA pre-sequencing, which prepares samples for subsequent sequencing reactions, making it a cornerstone of the sequencing protocol. Worldwide, NGS is increasingly integrated into medical laboratory analysis, disease evaluation, and diagnostics. In pharmacogenomics, NGS is widely utilized to accelerate drug discovery. Key innovations and developments by industry players aimed at enhancing diagnostic capabilities are expected to drive significant market growth in the coming years. For example, in March 2023, SOPHiA GENETICS partnered with Qiagen to advance tumor analysis through NGS. This collaboration combined QIAseq reagent technology with the SOPHiA DDM platform, enabling customers to access QIAseq panels processed via SOPHiA DDM(TM)-a cloud-based tool that analyzes data from various sources to unlock new research insights. Initially, the partnership focuses on homologous recombination repair (HRR), a biomarker test identifying tumors with mutations that may respond to PARP inhibitors in oncology, utilizing QIAseq Targeted DNA Pro panels for somatic variant detection.
- Regional Market Insights: The global next-generation sequencers market is segmented into North America, South America, Europe, the Middle East and Africa, and Asia Pacific. North America is projected to emerge as a leading market for NGS worldwide and is expected to maintain this dominance for several years. The growing adoption of NGS technology in routine clinical diagnostics is a key driver. Market expansion in this region is further supported by factors such as the increasing incidence of chronic and infectious diseases, rising investments in genomics, and significant advancements by major industry players. For instance, the Canadian Cancer Society estimates that 6,600 Canadians will be diagnosed with leukemia in 2024, while the US Department of Health and Human Services reported 62,770 new cases in the same year, representing 3.1% of all new cancer diagnoses. This rising disease burden is fueling demand for innovative detection and diagnostic solutions, propelling market growth throughout the forecast period.
Some of the major players covered in this report include Quest Diagnostics Incorporated, ARUP Laboratories, Applied Biological Materials, Inc. (ABM), Novogene Co., Ltd., Azenta Life Sciences (GENEWIZ), NanoString, among others.
Key Benefits of this Report:
- Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
- Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
- Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
- Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
- Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.
What do businesses use our reports for?
Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence
Report Coverage:
- Historical data from 2022 to 2024 & forecast data from 2025 to 2030
- Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
- Competitive Positioning, Strategies, and Market Share Analysis
- Revenue Growth and Forecast Assessment of segments and regions including countries
- Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)
The Next Generation Sequencers Market is segmented and analyzed as follows:
By Offering
By Technology
- Sequencing By Synthesis
- Ion Semiconductor Sequencing
- Single-molecule Real-time Sequencing
- Nanopore Sequencing
- Others
By Application
- Diagnostics
- Drug Discovery
- Biomarker Discovery
- Agriculture & Animal Research
- Others
By End-User
- Hospitals & Clinics
- Pharmaceutical & Biotechnology Companies
- Academics & Research Institutes
- Others
By Geography
- North America
- United States
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- United Kingdom
- Germany
- France
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Others
- Asia Pacific
- Japan
- China
- India
- South Korea
- Indonesia
- Thailand
- Others
TABLE OF CONTENTS
1. INTRODUCTION
- 1.1. Market Overview
- 1.2. Market Definition
- 1.3. Scope of the Study
- 1.4. Market Segmentation
- 1.5. Currency
- 1.6. Assumptions
- 1.7. Base and Forecast Years Timeline
- 1.8. Key benefits for the stakeholders
2. RESEARCH METHODOLOGY
- 2.1. Research Design
- 2.2. Research Process
3. EXECUTIVE SUMMARY
- 3.1. Key Findings
- 3.2. Analyst View
4. MARKET DYNAMICS
- 4.1. Market Drivers
- 4.2. Market Restraints
- 4.3. Porter's Five Forces Analysis
- 4.3.1. Bargaining Power of Suppliers
- 4.3.2. Bargaining Power of Buyers
- 4.3.3. The Threat of New Entrants
- 4.3.4. Threat of Substitutes
- 4.3.5. Competitive Rivalry in the Industry
- 4.4. Industry Value Chain Analysis
5. NEXT GENERATION SEQUENCERS MARKET BY OFFERING
- 5.1. Introduction
- 5.2. Product
- 5.3. Services
6. NEXT GENERATION SEQUENCERS MARKET BY TECHNOLOGY
- 6.1. Introduction
- 6.2. Sequencing By Synthesis
- 6.3. Ion Semiconductor Sequencing
- 6.4. Single-molecule Real-time Sequencing
- 6.5. Nanopore Sequencing
- 6.6. Others
7. NEXT GENERATION SEQUENCERS MARKET BY APPLICATION
- 7.1. Introduction
- 7.2. Diagnostics
- 7.3. Drug Discovery
- 7.4. Biomarker Discovery
- 7.5. Agriculture & Animal Research
- 7.6. Others
8. NEXT GENERATION SEQUENCERS MARKET BY END-USER
- 8.1. Introduction
- 8.2. Hospitals & Clinics
- 8.3. Pharmaceutical & Biotechnology Companies
- 8.4. Academics & Research Institutes
- 8.5. Others
9. NEXT GENERATION SEQUENCERS MARKET BY GEOGRAPHY
- 9.1. Global Overview
- 9.2. North America
- 9.2.1. United States
- 9.2.2. Canada
- 9.2.3. Mexico
- 9.3. South America
- 9.3.1. Brazil
- 9.3.2. Argentina
- 9.3.3. Others
- 9.4. Europe
- 9.4.1. United Kingdom
- 9.4.2. Germany
- 9.4.3. France
- 9.4.4. Spain
- 9.4.5. Others
- 9.5. Middle East and Africa
- 9.5.1. Saudi Arabia
- 9.5.2. UAE
- 9.5.3. Israel
- 9.5.4. Others
- 9.6. Asia-Pacific
- 9.6.1. Japan
- 9.6.2. China
- 9.6.3. India
- 9.6.4. South Korea
- 9.6.5. Indonesia
- 9.6.6. Thailand
- 9.6.7. Others
10. COMPETITIVE ENVIRONMENT AND ANALYSIS
- 10.1. Major Players and Strategy Analysis
- 10.2. Market Share Analysis
- 10.3. Mergers, Acquisitions, Agreements, and Collaborations
- 10.4. Competitive Dashboard
11. COMPANY PROFILES
- 11.1. Quest Diagnostics Incorporated
- 11.2. ARUP Laboratories
- 11.3. Applied Biological Materials, Inc. (ABM)
- 11.4. Novogene Co., Ltd.
- 11.5. Azenta Life Sciences (GENEWIZ)
- 11.6. NanoString
- 11.7. Illumina, Inc.
- 11.8. PacBio
- 11.9. Qiagen
- 11.10. Thermo Fisher Scientific